Circulating Exosomal CD30 And CD79B in Diffuse Large B-Cell Lymphoma Patients

Cansu Barış Moğul; Sibel Hacıoğlu; Nilay Şen Türk; Vildan Caner; Hande Şenol

Makale detayları

Circulating Exosomal CD30 And CD79B in Diffuse Large B-Cell Lymphoma Patients

Yazarlar:

Cansu Barış Moğul | Sibel Hacıoğlu | Nilay Şen Türk | Vildan Caner | Hande Şenol

Yayıncı:

Dokuz Eylul University

Ana Başlıklar:

Epigenetics | Gene Expression | Clinical Oncology | Medical Genetics (Excl. Cancer Genetics)

Dergi:

Journal of Basic and Clinical Health Sciences Vol.9 Issue 3, pp.593-603

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001359226

pISSN:

2564-7288

Anahtar kelimeler:

Özet:

 Purpose: Up to 30-40 of patients do not respond to treatment or relapse after R-CHOP chemoimmunotherapy in DLBCL. The predictive biomarkers for identifying candidates for new therapies have not been extensively studied. We aimed to determine the presence of CD3, CD19, CD20, CD30 and CD79B in plasma-derived exosomes from DLBCL patients and to compare the profiles of target proteins in exosomes and matched primary tumour tissue. Material and Methods: Exosome samples from 20 newly diagnosed DLBCL patients and 20 healthy controls from our previous studies were characterized according to the recent MISEV2018 guidelines. The presence of targeted antibodies in exosomes was determined by Western Blotting, while their expression in primary tumour tissue was analysed by immunohistochemistry. Results: Seventeen 85 patients had CD30-positive exosomes in their blood, while tumor cells expressing CD30 were found in only 2 10 patients. We only evaluated CD79B expression in tumor cells from 6 patients. Conclusion: In addition to tumor cells, characterising the factors present in the tumor microenvironment that support tumor cells, such as exosomes, will increase our success in treating DLBCL. Preclinical and clinical studies are needed to evaluate the presence of circulating CD30- and CD79B-positive exosomes in the selection of candidates for targeted immunotherapies using a non-invasive approach.

 Purpose: Up to 30-40 of patients do not respond to treatment or relapse after R-CHOP chemoimmunotherapy in DLBCL. The predictive biomarkers for identifying candidates for new therapies have not been extensively studied. We aimed to determine the presence of CD3, CD19, CD20, CD30 and CD79B in plasma-derived exosomes from DLBCL patients and to compare the profiles of target proteins in exosomes and matched primary tumour tissue. Material and Methods: Exosome samples from 20 newly diagnosed DLBCL patients and 20 healthy controls from our previous studies were characterized according to the recent MISEV2018 guidelines. The presence of targeted antibodies in exosomes was determined by Western Blotting, while their expression in primary tumour tissue was analysed by immunohistochemistry. Results: Seventeen 85 patients had CD30-positive exosomes in their blood, while tumor cells expressing CD30 were found in only 2 10 patients. We only evaluated CD79B expression in tumor cells from 6 patients. Conclusion: In addition to tumor cells, characterising the factors present in the tumor microenvironment that support tumor cells, such as exosomes, will increase our success in treating DLBCL. Preclinical and clinical studies are needed to evaluate the presence of circulating CD30- and CD79B-positive exosomes in the selection of candidates for targeted immunotherapies using a non-invasive approach.

 Purpose: Up to 30-40 of patients do not respond to treatment or relapse after R-CHOP chemoimmunotherapy in DLBCL. The predictive biomarkers for identifying candidates for new therapies have not been extensively studied. We aimed to determine the presence of CD3, CD19, CD20, CD30 and CD79B in plasma-derived exosomes from DLBCL patients and to compare the profiles of target proteins in exosomes and matched primary tumour tissue. Material and Methods: Exosome samples from 20 newly diagnosed DLBCL patients and 20 healthy controls from our previous studies were characterized according to the recent MISEV2018 guidelines. The presence of targeted antibodies in exosomes was determined by Western Blotting, while their expression in primary tumour tissue was analysed by immunohistochemistry. Results: Seventeen 85 patients had CD30-positive exosomes in their blood, while tumor cells expressing CD30 were found in only 2 10 patients. We only evaluated CD79B expression in tumor cells from 6 patients. Conclusion: In addition to tumor cells, characterising the factors present in the tumor microenvironment that support tumor cells, such as exosomes, will increase our success in treating DLBCL. Preclinical and clinical studies are needed to evaluate the presence of circulating CD30- and CD79B-positive exosomes in the selection of candidates for targeted immunotherapies using a non-invasive approach.

 Purpose: Up to 30-40 of patients do not respond to treatment or relapse after R-CHOP chemoimmunotherapy in DLBCL. The predictive biomarkers for identifying candidates for new therapies have not been extensively studied. We aimed to determine the presence of CD3, CD19, CD20, CD30 and CD79B in plasma-derived exosomes from DLBCL patients and to compare the profiles of target proteins in exosomes and matched primary tumour tissue. Material and Methods: Exosome samples from 20 newly diagnosed DLBCL patients and 20 healthy controls from our previous studies were characterized according to the recent MISEV2018 guidelines. The presence of targeted antibodies in exosomes was determined by Western Blotting, while their expression in primary tumour tissue was analysed by immunohistochemistry. Results: Seventeen 85 patients had CD30-positive exosomes in their blood, while tumor cells expressing CD30 were found in only 2 10 patients. We only evaluated CD79B expression in tumor cells from 6 patients. Conclusion: In addition to tumor cells, characterising the factors present in the tumor microenvironment that support tumor cells, such as exosomes, will increase our success in treating DLBCL. Preclinical and clinical studies are needed to evaluate the presence of circulating CD30- and CD79B-positive exosomes in the selection of candidates for targeted immunotherapies using a non-invasive approach.

Makale detayları

Circulating Exosomal CD30 And CD79B in Diffuse Large B-Cell Lymphoma Patients

Yazarlar:

Cansu Barış Moğul | Sibel Hacıoğlu | Nilay Şen Türk | Vildan Caner | Hande Şenol

Yayıncı:

Dokuz Eylul University

Ana Başlıklar:

Epigenetics | Gene Expression | Clinical Oncology | Medical Genetics (Excl. Cancer Genetics)

Dergi:

Journal of Basic and Clinical Health Sciences Vol.9 Issue 3, pp.593-603

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001359226

pISSN:

2564-7288

Non-Hodgkin Lymphoma

Diffuse Large B-cell Lymphoma

Exosome

CD30

CD79B

Sayı

Makale detayları

Circulating Exosomal CD30 And CD79B in Diffuse Large B-Cell Lymphoma Patients

Yazarlar: Cansu Barış Moğul | Sibel Hacıoğlu | Nilay Şen Türk | Vildan Caner | Hande Şenol

Yayıncı: Dokuz Eylul University

Ana Başlıklar: Epigenetics | Gene Expression | Clinical Oncology | Medical Genetics (Excl. Cancer Genetics)

Dergi: Journal of Basic and Clinical Health Sciences Vol.9 Issue 3, pp.593-603

Belge Tipi: Makale

Yayın Tarihi: 9/2025

Belge Dili: İngilizce

Document ID (Org No.): 2001359226

pISSN: 2564-7288

Non-Hodgkin Lymphoma

Diffuse Large B-cell Lymphoma

Exosome

CD30

CD79B

Sayı

Yazarlar:

Cansu Barış Moğul | Sibel Hacıoğlu | Nilay Şen Türk | Vildan Caner | Hande Şenol

Yayıncı:

Dokuz Eylul University

Ana Başlıklar:

Epigenetics | Gene Expression | Clinical Oncology | Medical Genetics (Excl. Cancer Genetics)

Dergi:

Journal of Basic and Clinical Health Sciences Vol.9 Issue 3, pp.593-603

Belge Tipi:

Makale

Yayın Tarihi:

9/2025

Belge Dili:

İngilizce

Document ID (Org No.):

2001359226

pISSN:

2564-7288